Document Detail


Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study.
MedLine Citation:
PMID:  19096845     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Helicobacter pylori eradication is useful for improvement of a half of patients with idiopathic thrombocytopenic purpura (ITP), but its long-term therapeutic efficacy has not been elucidated. We investigated the long-term efficacy of H. pylori eradication in 30 cases with ITP that were included in our previous study regarding the association between H. pylori infection and ITP. Twenty-one cases were positive and nine cases were negative for H. pylori infection. H. pylori eradication therapy including secondary regimen was successful in 20 cases, half (responder) of whom showed ITP remission 1 month later. Nine responders could be followed up for a long time and did not show re-infection of H. pylori. Eight of nine needed no medication except for eradication therapy. Another case remained in remission for 1 year but thereafter needed a steroid therapy due to the recurrence. Eight nonresponders could be followed up for a long time. All these cases showed a bad clinical course even though they received the other post-treatments including steroid therapy. Three of nine H. pylori-negative cases underwent eradication therapy after obtaining the written informed consent, but none of them showed improvement. Of these three cases, two cases could be followed up. Only one case remained a remission although receiving corticosteroid as a post-treatment. Conditions of H. pylori-negative ITP cases were usually unstable for a long time. H. pylori eradication has a short-term efficacy for about half of H. pylori-positive ITP patients, and the responders to the eradication therapy may receive a long-term clinical benefit without other therapies.
Authors:
C Tsumoto; K Tominaga; H Okazaki; T Tanigawa; H Yamagami; K Watanabe; T Nakao; K Koh; T Watanabe; Y Fujiwara; T Yamane; N Oshitani; M Hino; K Higuchi; T Arakawa
Related Documents :
2633355 - Clinical manifestations and therapy of heat stroke: consumptive coagulopathy successful...
12186105 - Severe graves ophthalmopathy accompanied by htlv-1-associated uveitis (hau) and anti-ne...
22040575 - Community survey, treatment and long-term follow-up for human cystic echinococcosis in ...
6937185 - A case of fournier's gangrene.
6691825 - Neurologic complications of hairy cell leukemia.
23797075 - Unanswered questions, the epidemiology of a community outbreak: meningococcal c disease...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2008-12-19
Journal Detail:
Title:  Annals of hematology     Volume:  88     ISSN:  1432-0584     ISO Abbreviation:  Ann. Hematol.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-06-17     Completed Date:  2009-07-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  789-93     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Adrenal Cortex Hormones / therapeutic use
Adult
Aged
Amoxicillin
Clarithromycin
Female
Follow-Up Studies
Helicobacter Infections / drug therapy
Helicobacter pylori / drug effects*
Humans
Male
Middle Aged
Platelet Count
Prospective Studies
Purpura, Thrombocytopenic, Idiopathic / virology*
Remission Induction
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Adrenal Cortex Hormones; 103577-45-3/lansoprazole; 26787-78-0/Amoxicillin; 81103-11-9/Clarithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Are "knife and fork" good enough for day case surgery of resistant tennis elbow?
Next Document:  Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of es...